989-P: Glycaemic Control, Hypoglycaemia Unawareness, and Diabetes-Related Distress in Middle-Old (75 to 85 Years), and Old-Old (>85) before and after Flash Glucose Monitoring in People Living with Diabetes—Association of British Clinical Diabetologist Study

Abstract

Introduction: There are limited data on the effect of intermittently scanned flash glucose monitoring (isCGM) on glycaemic control, hypoglycaemia unawareness and diabetes-related distress in middle-old (75 to 85 years) and old-old (≥85) people living with diabetes Methods: Clinicians were invited to submit isCGM data to a secure web-based tool held within the National Health services N3 network. We collected baseline data before FSL initiation, such as patient demographics, glycated haemoglobin (HbA1c) values from the previous 12 months, Gold score and Diabetes Distress Screening scale (DDS2) score. We compared the baseline clinical characteristics across the age categories using a t-test. All the analyses were done in R 4.1.2. Results: The study consisted of 16997 people with Type 1 diabetes with baseline and follow-up data, of which 342 were classified as middle-old, and 50 were classified as old-old (94% T1D). The use of isCGM was associated with significant improvement in Gold score in both middle-old (3.54 at baseline vs 3.02 at follow-up, P=0.04) and old-old populations (4.04 at baseline vs 2.72 at follow-up, P=0.01). The use of isCGM was also associated with significant improvement in DDS2 scores in both middle-old (2.53 at baseline vs 2.02 at follow-up, P<0.001) and old-old populations (2.40 at baseline vs 1.73 at follow-up, P<0.01). However, there was no significant effect of isCGM on glycaemic control in middle-old (64.2 mmol/mol at baseline vs 65.2 mmol/mol at follow-up, P=0.45) and old-old populations (60.3 mmol/mol at baseline vs 66.6 mmol/mol at follow-up, P=0.05). Conclusion: The use of isCGM was associated with significant improvement in diabetes-related distress and hypoglycaemia unawareness in middle-old and old-old people living with diabetes but did not affect glycaemic control in this population. Disclosure H.Deshmukh: None. E.G.Wilmot: Advisory Panel; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi, Roche Diabetes Care, Embecta, Consultant; Springer Healthcare, Research Support; Abbott Diabetes, Diabetes UK, Insulet Corporation, Novo Nordisk, NIH - National Institutes of Health, Speaker's Bureau; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi, Ypsomed AG, Glooko, Inc. C.Walton: None. R.E.Ryder: Other Relationship; Novo Nordisk, Speaker's Bureau; GI Dynamics, BioQuest. T.Sathyapalan: Other Relationship; Novo Nordisk, Abbott Diabetes, Research Support; Abbott Diabetes, Novo Nordisk, Eli Lilly and Company.